-
A New Hope for HER2-Positive Biliary Tract Cancer: FDA Approves Ziihera
NASDAQ: $JAZZ A Major Milestone in Oncology The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Ziihera (zanidatamab-hrii), marking a significant advancement for patients battling a specific, challenging form of cancer. This targeted therapy is now approved for the treatment of adult patients with unresectable or metastatic HER2-positive biliary tract cancer (BTC).…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-01-2026 TO 02-07-2026
The Groundhog sees his shadow, so hunker down and trade more to warm up! 😉 We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions…
$AMGN, $AZN, $BMY, $BSX, $DNLI, $GKOS, $GSK, $INCY, $JAZZ, $LLY, $MRNA, $PHVS, $REGN, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases